Alternatives to Adaptyv

AI-guided protein engineering that co-optimizes binding, stability, activity, and expression using your own wet-lab data.

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data for discovery teams.

Cloud-based medical imaging platform that turns MRI, CT, and PET scans into regulatory-cleared quantitative imaging biomarkers.

Exscientia now lives inside Recursion — an AI drug discovery engine built on automated wet labs and a 50+ PB dataset.

Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.

Clinical-stage AI drug discovery company running a wet-and-dry lab-in-the-loop engine with 2M weekly experiments and a 50+ PB phenomics dataset

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding, debugging, and controlling the internals of your AI models

Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease through partnership-led discovery.

Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.

Oncology real-world evidence platform turning patient data into AI-assisted cancer research insights.

All-in-human AI foundation models that predict brain activity and therapy response for CNS drug programs

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based simulation plus AI for molecular discovery across drug and materials design.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Tempus is an AI precision oncology platform that pairs tumor DNA/RNA sequencing with a 7M+ de-identified clinical record library for treatment and trial

AI-native biotech pairing 20+ petabytes of cellular experiments with population genetics to find causal drug targets

Cellino builds closed-loop, AI-guided bioprocessing hardware for personalized cell therapy manufacturing.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

PathAI is an enterprise digital pathology platform for diagnostic accuracy and biopharma drug development.

Clinical-stage TechBio company using cellular imaging and AI to discover drugs, with a Phase 1 MALT1 inhibitor and a Genentech neuroscience collaboration.

Dotmatics Luma: agentic AI that plans, executes, and completes R&D data analysis, report generation and platform configuration for multimodal scientific

AI platform that designs and predicts molecular constructs for gene and RNA therapies before they reach the lab

An AI co-scientist that chains 150+ biological tools to run multi-omics, clinical genomics, and drug discovery analysis from plain-language prompts.

Novaflow is an AI data analyst that turns raw biology data into publication-ready results without a terminal.

HealthKey scans your EHR daily and emails you clinical trial patients who match your protocol's eligibility criteria.

AI agents that assemble clinical evidence into quantitative models for trial design, dose selection and go/no-go decisions.

AI-CRISPR target discovery platform used by pharma partners to find causal immunology and oncology targets before committing to a program.

Cellbyte is an AI workspace for pharmaceutical Pricing & Market Access teams, turning HTA and pricing research from weeks into minutes.